Back | Table of Contents | Turkish Abstract | PDF | Mail to Author |

The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia

Salih AKSU¹, Fahri SAHIN², Burak UZ¹, Selim A. YAVUZ³, Hilmi ATAY⁴, Engin KELKITLI⁴, Mehmet TURGUT⁴, Mustafa PEHLIVAN⁵, Meltem O. AKAY⁶, Emel GURKAN⁷, Muzaffer DEMIR⁸, Selda KAHRAMAN⁹, Fatih DEMIRKAN⁹, Semra PAYDAS⁷, Güray SAYDAM², Ibrahim C. HAZNEDAROGLU<sup>1

1</sup>Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, TURKEY
²Ege University, Faculty of Medicine, Department of Hematology, Izmir, TURKEY
³Istanbul University, Faculty of Medicine, Department of Hematology, Istanbul, TURKEY
⁴Ondokuz Mayıs University, Faculty of Medicine, Department of Hematology, Samsun, TURKEY
⁵Gaziantep University Faculty of Medicine, Department of Hematology, Gaziantep, TURKEY
⁶Osmangazi University, Faculty of Medicine, Department of Hematology, Eskisehir, TURKEY
⁷Cukurova University, Faculty of Medicine, Department of Hematology, Adana, TURKEY
⁸Trakya University, Faculty of Medicine, Department of Hematology, Edirne, TURKEY
⁹Dokuz Eylül University, Faculty of Medicine, Department of Hematology, Izmir, TURKEY

Keywords: Chronic myeloid leukemia, Dasatinib, Treatment dosage

---

We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even lowdose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.

Back | Table of Contents | Turkish Abstract | PDF | Mail to Author |